AIM-HIGH misses its mark, but hits Abbott and the "HDL hypothesis"

Hopes of taking cardiovascular adverse event prevention to the next level by raising levels of the "good" HDL-cholesterol have been dealt another blow with the failure of the AIM-HIGH study of Abbott's extended-release niacin product Niaspan.

Hopes of taking cardiovascular adverse event prevention to the next level by raising levels of the "good" HDL-cholesterol have been dealt another blow with the failure of the AIM-HIGH study of Abbott's extended-release niacin product Niaspan.

The trial sponsor, the US National Heart Lung and Blood Institute, announced on 26 May that it had halted study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapeutic Category

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.